Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe N. Amaria, Amir A. Jazaeri, Robert A. Wolff et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 54
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signalingSamantha M. Fix, Amir A. Jazaeri, Marie‐Andrée Forget et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 44
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapyDonastas Sakellariou-Thompson, Chantale Bernatchez, Marie-Andrée Forget et al.|Cancer Immunology Immunotherapy|2019Cited by 28
172 Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineeringSamantha M. Fix, Amir A. Jazaeri, Marie‐Andrée Forget et al.|Regular and Young Investigator Award Abstracts|2021Cited by 1